PADMA-28, a traditional Tibetan herbal preparation, blocks cellular responses to bFGF and IGF-I

Inflammopharmacology

Volumn 12, Issue 4, 2004, Pages 373-389

  Navab, Roya ^a   Aingorn, Helena ^b   Fallavollita, Lucia ^a   Sallon, Sara ^b   Mechoulam, Raphael ^c   Ginsburg, Isaac ^c   Vlodavsky, Israel ^d   Brodt, Pnina ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Atherosclerosis; bFGF; IGF I; PADMA 28

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; PADMA 28; PLANT EXTRACT; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; BYPASS SURGERY; CELL PROLIFERATION; CHINA; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG MIXTURE; HERBAL MEDICINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; METASTASIS; MITOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER; TRANSLUMINAL CORONARY ANGIOPLASTY; TUMOR GROWTH; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIOSCLEROSIS; CATTLE; CELL PROLIFERATION; DNA; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; INSULIN-LIKE GROWTH FACTOR I; MUSCLE, SMOOTH, VASCULAR; PLANT EXTRACTS; RECEPTOR, IGF TYPE 1; RNA, MESSENGER;

EID: 21344457918     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/1568560043696227     Document Type: Article

References (42)

1. Balaram, S. K., Agrawal, D. K., Allen, R. T., et al. (1997). Cell adhesion molecules and insulin-like growth factor-1 in vascular disease, J. Vasc. Surg. 25, 866-876.
2. Bar-Shavit, R., Benezra, M., Eldor, A., et al. (1990). Thrombin immobilized to extracellular matrix is a mitogen for vascular smooth muscle cells: Non-enzymatic mode of action, Cell Regul. 1, 453-463.
3. Bayes-Genis, A., Conover, C. A. and Schwartz, R. S. (2000). The insulin-like growth factor axis: A review of atherosclerosis and restenosis, Circ. Res. 86, 125-130.
4. Benezra, M., Ben-Sasson, S. A., Regan, J., et al. (1994). Antiproliferative activity towards vascular smooth muscle cells and receptor binding of heparin-mimicking anionic aromatic compounds, Arterioscler. Throm. 14, 1992-1999.
5. Burgess, W. H. and Maciag, T. (1989). Heparin-binding (fibroblast) growth factor family of proteins, Annu. Rev. Biochem. 58, 575-606.
6. Clemmons, D., Jones, J., Busby, W., et al. (1993). Role of insulin-like growth factor binding proteins in modifying IGF actions, N.Y. Acad. Sci. 692, 10-21.
7. Cross, M. and Dexter, T. M. (1991). Growth factors in development, transformation, and tumourigenesis, Cell 64, 271-280.
8. Drabaek, H., Mehlsen, J., Himmelstrup, H., et al. (1993). A botanical compound PADMA-28 increases walking distance in stable intermittent claudication, Angiology 44, 863-867.
9. Edelman, E. R., Nugent, M. A., Smith, L. T., et al. (1992). Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries, J. Clin. Invest. 89, 465-473.
10. Elkin, M., Ilan, N., Ishai-Michaeli, R., et al. (2001). Heparanase as mediator of angiogenesis: mode of action, FASEB J. 15, 1661-1663.
11. Ferns, G. A., Motani, A. S. and Anggard, E. E. (1991). The insulin-like growth factors: their putative role in atherogenesis, Artery 18, 197-225.
12. Ferns, G. A. A., Rains, E. W., Sprugel, K. H., et al. (1991). Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF, Science 253, 1129-1132.
13. Ginsburg, I., Sadovnik, M., Sallon, S., et al. (1999). PADMA-28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by a mixture of oxidants and pro-inflammatory agonists and peroxidation of lipids, Immunopharmacology 7, 47-62.
14. Gospodarowicz, D., Moran, J., Braun, D., et al. (1976). Clonal growth of bovine vascular endothelial cells in tissue culture: fibroblast growth factor as a survival agent, Proc. Natl. Acad. Sci. USA 73, 4120-4124.
15. Hochberg, Z., Hertz, P., Maor, G., et al. (1992). Growth hormone and insulin-like growth factor-I increase macrophage uptake and degradation of low density lipoprotein, Endocrinology 131, 430-435.
16. Jawien, A., Bowen-Pope, D. F., Linder, V., et al. (1992). Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty, J. Clin. Invest. 89, 507-511.
17. Kamide, K., Hori, M. T., Zhu, J. H., et al. (2000). Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells, J. Hypertension 18, 1051-1056.
18. LeRoith, D., Clemmons, D., Nissley, P., et al. (1992). NIH conference. Insulin-like growth factors in health and disease, Ann. Intern. Med. 116, 854-862.
19. Libby, P., Ridker, P. M. and Maseri, A. (2002). Inflammation and atherosclerosis, Circulation 105, 1135-1143.
20. Lindner, V., Lappi, D. A., Baird, R., et al. (1991). Role of basic fibroblast growth factor in vascular lesion formation, Circ. Res. 68, 106-113.
21. Liu, W., Liu, Y. and Lowe Jr., W. L. (2001). The role of phosphatidylinositol 3-kinase and the mitogen-activated protein kinases in insulin-like growth factor-I-mediated effects in vascular endothelial cells, Endocrinology 142, 1710-1719.
22. Long, L., Nip, J. and Brodt, P. (1994). Paracrine growth stimulation by hepatocyte-derived IGF-I: A regulatory mechanism for carcinoma cells metastatic to the liver, Cancer Res. 54, 3732-3737.
23. Long, L., Rubin, R. and Brodt, P. (1998). Increased invasive and metastatic potential in tumour cells over-expressing the receptor for type 1 insulin-like growth factor receptor, Exp. Cell Res. 238, 116-121.
24. Long, L., Rubin, R., Baserga, R., et al. (1995). Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res. 55, 1006-1009.
25. Loppnow, H. and Libby, P. (1990). Proliferating or interleukin-1 activated human vascular smooth muscle cells secrete copious interleukin-6, J. Clin. Invest. 85, 731-738.
26. Matzner, Y. and Sallon, S. (1995). The effect of PADMA-28, a traditional Tibetan herbal preparation on human neutrophil function, J. Clin. Lab. Immunol. 46, 13-23.
27. McBride, W., Lange, R. A. and Hillis, L. D. (1988). Restenosis after successful coronary angioplasty, N. Engl. J. Med. 318, 1734-1737.
28. Medalion, B., Merin, G., Aingorn, H., et al. (1997). Endogenous basic fibroblast growth factor displaced by heparin from the luminal surface of human blood vessels is preferentially sequestered by injured regions of the vessel wall, Circulation 95, 1853-1862.
29. Navab, R., Chevet, E., Authier, F., et al. (2001). Endosomal processing of IGF-I is required for cancer cells growth and tumourigenicity, J. Biol. Chem. 276, 13644-13649.
30. Raab, G. and Klagsbrun, M. (1997). Heparin-binding EGF-like growth factor, Biochim. Biophys. Acta 1333, F179-F99.
31. Rifici, V. A., Schneider, S. H. and Khachadurian, A. K. (1994). Stimulation of low-density lipoprotein oxidation by insulin and insulin like growth factor, Atherosclerosis 107, 99-108.
32. Ross, R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s, Nature 362, 801-809.
33. Rubin, R. and Baserga, R. (1995). Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumourigenicity, Lab. Invest. 73, 311-331.
34. Ruotolo, G., Bavenholm, P., Brismar, K., et al. (2000). Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment, J. Am. Coll. Cardiol. 35, 647-654.
35. Sallon, S., Beer, G., Rosenfeld, J., et al. (1998). The efficacy of PADMA 28 a herbal preparation, in the treatment of intermittent claudication: a controlled double-blind pilot study with objective assessment of chronic occlusive arterial disease patients, J. Vasc. Invest. 4, 129-136.
36. Samani, A. and Brodt, P. (2001). The receptor for the type I insulin like growth factor and its ligands regulate multiple cellular functions which impact on metastasis, Surg. Oncol. Clin. North Am. 10, 289-312.
37. Schwartz, S. M. (1993). Serum-derived growth factor is thrombin?, J. Clin. Invest. 91, 4.
38. Tsukada, T., Tippens, D., Gordon, D., et al. (1987). HHF35, a muscle actin specific monoclonal antibody. I. Immunocytochemical and biochemical characterization, Am. J. Pathol. 126, 51-60.
39. Vlodavsky, I., and Christofori, G. (1998). Fibroblast growth factors in tumour progression and angiogenesis, in: Antiangiogenic Agents in Cancer Therapy, Teicher, B. A. (Ed.), pp. 93-118. Humana Press, Totowa, NJ.
40. Vlodavsky, I., Bar-Shavit, R., Ishai-Michaeli, R., et al. (1991). Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?, Trends Biochem. Sci. 16, 268-271.
41. Vlodavsky, I., Bar-Shavit, R., Korner, G., et al. (1993). Extracellular matrix-bound growth factors, enzymes and plasma proteins, in: Basement Membranes: Cellular and Molecular Aspects, Rohrbach, D. H. and Timpl, R. (Eds), pp. 327-343. Academic Press, Orlando, FL.
42. Winther, K., Kharazmi, A., Himmelstrap, H., et al. (1994). PADMA-28: a botanical compound, decreases the oxidation response of monocytes and improves fibrinolysis in patients with stable intermittent claudication, Fibrinolysis 2 (Suppl.), 47-49.